Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

NA598 remain susceptible to current SOC, consistent with prior in vitro results.

Anadys has completed two long-term chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys). The No Observed Adverse Effect Level, or NOAEL, is 1000 mg/kg, the highest dose tested, in both the rat and monkey. The completed toxicology studies support the ongoing Phase II clinical study as well as future clinical studies of longer duration.

Anadys has presented in vitro data supporting the use of ANA598 in combination with interferon-alpha as well as with direct antivirals currently in development. In particular, data has shown that ANA598 is synergistic in vitro with interferon-alpha as well as representative HCV protease and polymerase inhibitors. In vitro combination treatment at clinically relevant concentrations of interferon-alpha and ANA598 results in clearance of HCV RNA from cells rather than selection of resistant isolates. Furthermore, ANA598 retains full activity in vitro against mutations conferring resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct from that of ANA598, and protease and nucleoside polymerase inhibitors retain full activity in vitro against mutations conferring resistance to ANA598.

ANA598 has received Fast Track Status from the FDA for the treatment of chronic hepatitis C.

Conference Call Webcast and Slides

Anadys will host a conference call today, December 17, 2009 at 8:30 a.m. Eastern Standard Time (5:30 a.m. Pacific Standard Time) to discuss the 4-week results from the first cohort of the ongoing Phase II clinical trial of ANA598 in combination with SOC. A live webcast of the call, including accompanying slides, will be available online at

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... (USPTO) has issued a key patent covering ImmunoCellular,s ... targeting six tumor antigens that are commonly expressed ... 8,871,211, which issued October 28, 2014, include methods ... cell composition comprising peptide epitopes of the six ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... term follow up results from chronically infected Hepatitis C,patients strongly confirm and exceed ... to show a statistically significant and long-term ... the way and strongly support move into a second generation, vaccine formulated ... ...
... the risk of,stroke by 34% in patient with atrial fibrillation ... adequately treated by ... of a,post-hoc analysis of the data from the ATHENA study ... European Society of Cardiology,congress 2008, in Munich, Germany. Previous results ...
Cached Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5
(Date:12/20/2014)... December 20, 2014 Recently, AngelWeddingDress.com has ... Discount ”) for the coming Christmas. In the promotion, ... 80% off. , “We have something special for the ... the holiday season. Moreover, our new collections of 2015 ... are offered now at greatly discounted prices. Visit our ...
(Date:12/20/2014)... 2014 Today, Balfleet.com, one of the ... Sale, offering 50%-70% off on its Mother of ... The mother of the bride dresses from Balfleet.com feature ... 24/7 accessible and takes pride in providing high quality ... are offering great discounts on our mother of the ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... 2014 These vanadium reserves are mostly ... Around 151,000 tons of vanadium were produced globally in ... usage increased at 6.7% AAGR during the period from ... industry, being the largest consumer, accounted for more than ... titanium-vanadium alloy and the chemical industry. , View Full ...
(Date:12/19/2014)... 2014 (HealthDay News) -- The intestinal bacteria that cause ... colitis, may be inherited, researchers report. The findings, ... could help in efforts to prevent the disease and ... the study authors added. "The intestinal bacteria, or ... can have a big impact on your health for ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2
... Corporation,(Nasdaq: MDTH ) announced that its senior management ... 2008 Health Care Conference,held May 13 - 15 at ... senior management will give its presentation on Tuesday, May,13 ... web cast live over,the Internet via MedCath,s website ( ...
... TORONTO, May 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals ... development and,commercialization of cancer therapies, today announced ... Operational Highlights, During the three ... achieved the,following steps in preparation for the ...
... Two Operations Leads to Indictment of 11,Defendants in ... people have been,indicted in the second phase of ... and health care companies that,fraudulently bill the Medicare ... S. Fisher and U.S. Attorney for the Central,District ...
... May 8 HealthSouth,Corporation (NYSE: HLS ) today ... things, elect directors and provide an update on the,company,s ... More than 88.5% of the outstanding shares eligible ... or by proxy and the board,s,nominated slate of directors ...
... PHOENIX, May 8 NutraCea (OTC Bulletin Board:,NTRZ), ... nutrient research and,technology, announced today that it will ... 12 after the market closes., Management will ... Monday, May,12th to review the first quarter financial ...
... 8 Shortly after the gruesome,discovery of aborted babies ... in early March, Citizens for a Pro-Life Society,discovered the ... Advisory Clinic in Livonia, Michigan, owned by Dr. Reginald ... times in which we live that we,must stop and ...
Cached Medicine News:Health News:Bradmer announces 2008 first quarter operational and financial results 2Health News:Bradmer announces 2008 first quarter operational and financial results 3Health News:Bradmer announces 2008 first quarter operational and financial results 4Health News:Bradmer announces 2008 first quarter operational and financial results 5Health News:Bradmer announces 2008 first quarter operational and financial results 6Health News:Bradmer announces 2008 first quarter operational and financial results 7Health News:Bradmer announces 2008 first quarter operational and financial results 8Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 2Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 3Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 4Health News:Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 5Health News:HealthSouth Board Re-Elected at Annual Shareholder Meeting 2Health News:NutraCea to Host First Quarter 2008 Conference Call on May 12. 2Health News:ALL: More Dead Babies Found in Michigan Dumpsters 2
... super-light polypropylene mesh which offers an excellent ... considerably. Optilene Mesh LP is the alternative ... procedures. It perfectly conforms,to anatomical structures. Due ... adapts to the movements of the patient ...
... LP is a lightweight polypropylene mesh ... considerably reduced,foreign body reaction. The softer, ... It perfectly conforms to,anatomical structures. Due ... LP adapts to the movements of ...
... The Celsius Control System ... that can safely,and rapidly lower ... chosen target temperature and,rewarm patients ... Control System consists of an ...
... pump" coronary artery surgery is the latest ... is being embraced world-wide by increasing numbers ... subtle but reduced mortality, stroke, and bleeding ... benefits. A cardiac stabilizer is mandatory for ...
Medicine Products: